Researchers urge FDA to emulate EMA's transparency in drug rejection letters
A group of researchers argues that the FDA's recent move to publish drug rejection letters should be refined by adopting practices from the European Medicines Agency. They suggest that the US agency can improve the clarity and completeness of its disclosures. The comparison highlights differences in how the two regulators communicate negative decisions to the public.
The Food and Drug Administration has recently begun releasing letters that explain its denials of drug applications. A cohort of researchers now contends that this initial transparency effort could be strengthened by looking to the European Medicines Agency for guidance.
The researchers point to a divergence in how the two agencies frame negative outcomes. They suggest that adopting the EMA's approach could yield more thorough and understandable disclosures, ultimately providing clearer reasons for regulatory rejections to the public.
This push for greater regulatory transparency could affect patients, clinicians, and pharmaceutical developers. Clearer rejection letters may help the public understand why certain therapies are withheld, potentially fostering trust in the approval process. For drugmakers, more detailed feedback might reduce ambiguity around failed applications, possibly guiding future research. However, the impact depends on how effectively the FDA adapts these practices, as improved clarity could also invite more scrutiny of its decision-making.